A Mechanism by which Ergosterol Inhibits the Promotion of Bladder Carcinogenesis in Rats
Open Access
- 27 June 2020
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 8 (7), 180
- https://doi.org/10.3390/biomedicines8070180
Abstract
We previously showed that ergosterol has an inhibitory effect on bladder carcinogenesis. In this study, we aimed to elucidate the molecular mechanism by which ergosterol inhibits bladder carcinogenesis using a rat model of N-butyl-N-(4-hydroxybutyl)nitrosamine-induced bladder cancer. The messenger ribonucleic acid (mRNA) expression level of the cell cycle-related gene cyclin D1 and inflammation-related gene cyclooxygenase-2 in bladder epithelial cells was significantly increased in the carcinogenesis group compared with the control group. In contrast, in ergosterol-treated rats, these increases were significantly suppressed. Ergosterol did not affect the plasma testosterone concentration or the binding of dihydrotestosterone to androgen receptor (AR). The mRNA expression levels of 5α-reductase type 2 and AR were higher in the carcinogenesis group than in the control group but were significantly decreased by ergosterol administration. These results suggest that ergosterol inhibits bladder carcinogenesis by modulating various aspects of the cell cycle, inflammation-related signaling, and androgen signaling. Future clinical application of the preventive effect of ergosterol on bladder carcinogenesis is expected.This publication has 39 references indexed in Scilit:
- The Role of the Androgen Receptor in the Development and Progression of Bladder CancerJapanese Journal of Clinical Oncology, 2012
- NF‐κB inhibitory activity of compounds isolated from Cantharellus cibariusPhytotherapy Research, 2008
- Promotion of Bladder Cancer Development and Progression by Androgen Receptor SignalsJNCI Journal of the National Cancer Institute, 2007
- Ergosterol peroxide from an edible mushroom suppresses inflammatory responses in RAW264.7 macrophages and growth of HT29 colon adenocarcinoma cellsBritish Journal of Pharmacology, 2007
- Prostaglandin E2 Enhances Intestinal Adenoma Growth via Activation of the Ras-Mitogen-Activated Protein Kinase CascadeCancer Research, 2005
- Nuclear transcription factor-κB as a target for cancer drug developmentLeukemia, 2002
- Nuclear Factor-κB Activation: A Question of Life or DeathBMB Reports, 2002
- PGE2 Stimulates VEGF Expression in Endothelial Cells via ERK2/JNK1 Signaling PathwaysBiochemical and Biophysical Research Communications, 2001
- Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression.JCI Insight, 1993
- Concanavalin a agglutination of bladder cells of rats treated with bladder carcinogens; A rapid new test to detect bladder carcinogensCancer Letters, 1978